Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

IKKβ overexpression together with a lack of tumour suppressor genes causes ameloblastic odontomas in mice

  • Page, Angustias
  • Bravo Moral, Ana María
  • Suárez Cabrera, Cristian
  • Sánchez Baltasar, Raquel
  • Oteo, Marta
  • Morcillo, Miguel Ángel
  • Llanos Casanova, M.
  • Segovia, José C.
  • Navarro, Manuel
  • Ramírez, Ángel
Odontogenic tumours are a heterogeneous group of lesions that develop in the oral cavity region and are characterized by the formation of tumoural structures that differentiate as teeth. Due to the diversity of their histopathological characteristics and clinical behaviour, the classification of these tumours is still under debate. Alterations in morphogenesis pathways such as the Hedgehog, MAPK and WNT/β-catenin pathways are implicated in the formation of odontogenic lesions, but the molecular bases of many of these lesions are still unknown. In this study, we used genetically modified mice to study the role of IKKβ (a fundamental regulator of NF-κB activity and many other proteins) in oral epithelial cells and odontogenic tissues. Transgenic mice overexpressing IKKβ in oral epithelial cells show a significant increase in immune cells in both the oral epithelia and oral submucosa. They also show changes in the expression of several proteins and miRNAs that are important for cancer development. Interestingly, we found that overactivity of IKKβ in oral epithelia and odontogenic tissues, in conjunction with the loss of tumour suppressor proteins (p53, or p16 and p19), leads to the appearance of odontogenic tumours that can be classified as ameloblastic odontomas, sometimes accompanied by foci of secondary ameloblastic carcinomas. These tumours show NF-κB activation and increased β-catenin activity. These findings may help to elucidate the molecular determinants of odontogenic tumourigenesis and the role of IKKβ in the homoeostasis and tumoural transformation of oral and odontogenic epithelia
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells

  • Martinez-Lage , Marta|||0000-0001-5535-025X
  • Torres, Raul|||0000-0001-9606-0398
  • Puig-Serra, Pilar|||0000-0002-7802-4972
  • Moreno-Gaona, Patricia
  • Martin, M. Carmen
  • Moya, Francisco J.
  • Quintana-Bustamante, Oscar|||0000-0002-6869-7006
  • Garcia-Silva, Susana|||0000-0003-1065-0245
  • Carcaboso, Angel M.|||0000-0002-8485-426X
  • Petazzi, Paolo|||0000-0002-1036-2895
  • Bueno, Clara|||0000-0003-1442-6216
  • Català-Mora, Jaume|||0000-0003-2152-8579
  • Peinado, Héctor|||0000-0002-4256-3413
  • Segovia, Jose C.|||0000-0003-4101-6124
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Rodriguez-Perales, Sandra|||0000-0001-7221-3636
Fusion oncogenes (FOs) are common in many cancer types and are powerful drivers of tumor development. Because their expression is exclusive to cancer cells and their elimination induces cell apoptosis in FO-driven cancers, FOs are attractive therapeutic targets. However, specifically targeting the resulting chimeric products is challenging. Based on CRISPR/Cas9 technology, here we devise a simple, efficient and non-patient-specific gene-editing strategy through targeting of two introns of the genes involved in the rearrangement, allowing for robust disruption of the FO specifically in cancer cells. As a proof-of-concept of its potential, we demonstrate the efficacy of intron-based targeting of transcription factors or tyrosine kinase FOs in reducing tumor burden/mortality in in vivo models. The FO targeting approach presented here might open new horizons for the selective elimination of cancer cells.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Gene editing of PKLR gene in human hematopoietic progenitors through 5' and 3' UTR modified TALEN mRNA

  • Quintana-Bustamante, Oscar|||0000-0002-6869-7006
  • Fañanas-Baquero, S.
  • Orman, I.
  • Torres, Raul|||0000-0001-9606-0398
  • Duchateau, P.
  • Poirot, L.
  • Gouble, A.
  • Bueren, Juan|||0000-0002-3228-7013
  • Segovia, J. C.
Pyruvate Kinase Deficiency (PKD) is a rare erythroid metabolic disease caused by mutations in the PKLR gene, which encodes the erythroid specific Pyruvate Kinase enzyme. Erythrocytes from PKD patients show an energetic imbalance and are susceptible to hemolysis. Gene editing of hematopoietic stem cells (HSCs) would provide a therapeutic benefit and improve safety of gene therapy approaches to treat PKD patients. In previous studies, we established a gene editing protocol that corrected the PKD phenotype of PKD-iPSC lines through a TALEN mediated homologous recombination strategy. With the goal of moving toward more clinically relevant stem cells, we aim at editing the PKLR gene in primary human hematopoietic progenitors and hematopoietic stem cells (HPSCs). After nucleofection of the gene editing tools and selection with puromycin, up to 96% colony forming units showed precise integration. However, a low yield of gene edited HPSCs was associated to the procedure. To reduce toxicity while increasing efficacy, we worked on i) optimizing gene editing tools and ii) defining optimal expansion and selection times. Different versions of specific nucleases (TALEN and CRISPR-Cas9) were compared. TALEN mRNAs with 5' and 3' added motifs to increase RNA stability were the most efficient nucleases to obtain high gene editing frequency and low toxicity. Shortening ex vivo manipulation did not reduce the efficiency of homologous recombination and preserved the hematopoietic progenitor potential of the nucleofected HPSCs. Lastly, a very low level of gene edited HPSCs were detected after engraftment in immunodeficient (NSG) mice. Overall, we showed that gene editing of the PKLR gene in HPSCs is feasible, although further improvements must to be done before the clinical use of the gene editing to correct PKD. Institutode Investigacio ' n Sanitaria de la Fundacio ' n.